Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (15223)	2/18/1998 7:09:00 PM
From: HerbertOtto	Respond to of 32384

LGND's choice of Panretin for KS will help them get their first drug approval quickly, and put them among the small group of biotechs that can get the whole job done for investors. The credibility that generates should help finance the next drug development. When Wall St. starts to believe in LGND, and starts to discount the future drug stream, LGND will - like all other successful stocks - sell at a dizzying price. Many never justify those prices... but some do. Herbert